WO2012077968A3 - Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation - Google Patents

Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation Download PDF

Info

Publication number
WO2012077968A3
WO2012077968A3 PCT/KR2011/009413 KR2011009413W WO2012077968A3 WO 2012077968 A3 WO2012077968 A3 WO 2012077968A3 KR 2011009413 W KR2011009413 W KR 2011009413W WO 2012077968 A3 WO2012077968 A3 WO 2012077968A3
Authority
WO
WIPO (PCT)
Prior art keywords
valsartan
lercanidipine hydrochloride
preparation
present
complex formulation
Prior art date
Application number
PCT/KR2011/009413
Other languages
English (en)
Other versions
WO2012077968A2 (fr
Inventor
Young Sik Chung
Soo Ah Park
Ree Sun Kim
Sung Il Kim
Jae Hyeon Juhn
Dong Kyu Kim
Yoo Rin Kim
Hee Dong Park
Seong Jae Park
Sung Hack Lee
Ju Hyun Kim
Min Young Jung
Original Assignee
Lg Life Sciences Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012077968(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UAA201307936A priority Critical patent/UA108277C2/ru
Priority to SG2013038211A priority patent/SG190326A1/en
Priority to MX2013005716A priority patent/MX2013005716A/es
Priority to BR112013013415A priority patent/BR112013013415A2/pt
Priority to CN201180058951.9A priority patent/CN103249415B/zh
Application filed by Lg Life Sciences Ltd. filed Critical Lg Life Sciences Ltd.
Priority to AU2011339150A priority patent/AU2011339150B2/en
Priority to EP11847739.7A priority patent/EP2648730A4/fr
Priority to EA201390844A priority patent/EA201390844A1/ru
Publication of WO2012077968A2 publication Critical patent/WO2012077968A2/fr
Publication of WO2012077968A3 publication Critical patent/WO2012077968A3/fr
Priority to TNP2013000212A priority patent/TN2013000212A1/fr
Priority to IL226449A priority patent/IL226449A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La présente invention concerne une composition pharmaceutique contenant de l'hydrochlorure de lercanidipine et du valsartan en tant que principes actifs, ainsi que son procédé de préparation. La composition pharmaceutique contenant de l'hydrochlorure de lercanidipine et du valsartan selon la présente invention se révèle extrêmement efficace en matière de prévention et de traitement des maladies cardiovasculaires et des maladies associées, et a pour effet de réduire les effets indésirables de chaque composant. En outre, dans la présente composition, l'hydrochlorure de lercanidipine et le valsartan se présentent sous une forme distincte, ce qui a pour résultat une augmentation de la vitesse de dissolution des deux composants et une réduction des effets indésirables.
PCT/KR2011/009413 2010-12-09 2011-12-07 Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation WO2012077968A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EA201390844A EA201390844A1 (ru) 2010-12-09 2011-12-07 Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
SG2013038211A SG190326A1 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
MX2013005716A MX2013005716A (es) 2010-12-09 2011-12-07 Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma.
BR112013013415A BR112013013415A2 (pt) 2010-12-09 2011-12-07 composição farmacêutica, e, método para a preparação de uma composição
CN201180058951.9A CN103249415B (zh) 2010-12-09 2011-12-07 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
UAA201307936A UA108277C2 (ru) 2010-12-09 2011-12-07 Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения
AU2011339150A AU2011339150B2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
EP11847739.7A EP2648730A4 (fr) 2010-12-09 2011-12-07 Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation
TNP2013000212A TN2013000212A1 (en) 2011-12-07 2013-05-15 Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof
IL226449A IL226449A0 (en) 2010-12-09 2013-05-20 A complex formulation containing larcanidipin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0125804 2010-12-09
KR20100125804 2010-12-09

Publications (2)

Publication Number Publication Date
WO2012077968A2 WO2012077968A2 (fr) 2012-06-14
WO2012077968A3 true WO2012077968A3 (fr) 2012-07-26

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/009413 WO2012077968A2 (fr) 2010-12-09 2011-12-07 Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation

Country Status (17)

Country Link
EP (1) EP2648730A4 (fr)
KR (1) KR101414814B1 (fr)
CN (1) CN103249415B (fr)
AR (1) AR084195A1 (fr)
AU (1) AU2011339150B2 (fr)
BR (1) BR112013013415A2 (fr)
CL (1) CL2013001626A1 (fr)
CO (1) CO6721030A2 (fr)
DO (1) DOP2013000115A (fr)
EA (1) EA201390844A1 (fr)
IL (1) IL226449A0 (fr)
MX (1) MX2013005716A (fr)
PE (1) PE20140699A1 (fr)
SG (1) SG190326A1 (fr)
UA (1) UA108277C2 (fr)
UY (1) UY33772A (fr)
WO (1) WO2012077968A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
CN105163734A (zh) * 2013-03-12 2015-12-16 株式会社Lg生命科学 包含缬沙坦及罗舒伐他汀钙的复合制剂及其制造方法
WO2019008485A1 (fr) 2017-07-06 2019-01-10 Mankind Pharma Ltd Composition pharmaceutique à dose fixe à base de valsartan et de sacubitril
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20070105912A1 (en) * 2003-12-01 2007-05-10 Per Holm Pharmaceutical compositions comprising lercanidipine
US20100047341A1 (en) * 2006-10-10 2010-02-25 Hanall Pharmaceutical Co., Ltd. Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5110697B2 (ja) 2005-06-27 2012-12-26 第一三共株式会社 固形製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20070105912A1 (en) * 2003-12-01 2007-05-10 Per Holm Pharmaceutical compositions comprising lercanidipine
US20100047341A1 (en) * 2006-10-10 2010-02-25 Hanall Pharmaceutical Co., Ltd. Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory

Also Published As

Publication number Publication date
AU2011339150B2 (en) 2015-09-10
CO6721030A2 (es) 2013-07-31
DOP2013000115A (es) 2014-07-31
EA201390844A1 (ru) 2013-11-29
AR084195A1 (es) 2013-04-24
KR101414814B1 (ko) 2014-07-21
AU2011339150A1 (en) 2013-06-06
CN103249415A (zh) 2013-08-14
PE20140699A1 (es) 2014-06-13
CN103249415B (zh) 2017-12-12
CL2013001626A1 (es) 2013-10-04
KR20120089787A (ko) 2012-08-13
IL226449A0 (en) 2013-07-31
EP2648730A2 (fr) 2013-10-16
WO2012077968A2 (fr) 2012-06-14
EP2648730A4 (fr) 2014-08-06
UY33772A (es) 2012-07-31
MX2013005716A (es) 2013-06-12
UA108277C2 (ru) 2015-04-10
SG190326A1 (en) 2013-06-28
BR112013013415A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
WO2011076749A3 (fr) Forme solide de dosage pharmaceutique
WO2011099832A3 (fr) Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
EP2522653A4 (fr) Dérivé de biguanide, procédé de préparation de celui-ci et composition pharmaceutique contenant le dérivé de biguanide en tant que substance active
WO2012042224A8 (fr) Composition pharmaceutique
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2010111640A3 (fr) Compositions antigrippales et méthodes associées
WO2012162439A3 (fr) Compositions comprenant de l'acide fusidique et leurs emballages
WO2013112959A8 (fr) Composés antifibrotiques et leurs utilisations
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2014203275A3 (fr) Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires
WO2012053009A3 (fr) Compositions pharmaceutiques comprenant des agents de décoloration de la peau
WO2010090494A3 (fr) Utilisation médicale de dérivés d'acide 5-benzylaminosalicylique ou de sels correspondants
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2012077968A3 (fr) Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation
WO2012024583A3 (fr) Composés oxystérol
WO2014064652A3 (fr) Composition pharmaceutique stable d'interféron pégylé alpha-2b
WO2013100718A3 (fr) Composition pharmaceutique permettant de prévenir ou de traiter des maladies inflammatoires ou l'asthme, contenant un extrait de lagerstroemia ovalifolia ou une fraction de celle-ci en tant que principe actif
WO2012155226A8 (fr) Procédé pour la production de dérivés de pyrostegia venusta, dérivés de pyrostegia venusta, compositions pharmaceutiques et leurs utilisations
WO2014001267A3 (fr) Forme galénique pour la libération de principes actifs
WO2012007758A3 (fr) Formulations pharmaceutiques
WO2009108017A3 (fr) Nouveaux dérivés de pyruvate avec effet neuroprotecteur, processus de préparation de ceux-ci et composition pharmaceutique comprenant ces dérivés
TN2013000212A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof
WO2011139255A3 (fr) Compositions pharmaceutiques comprenant du céfétamet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847739

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12013500980

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 226449

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/005716

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 001346-2013

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2011339150

Country of ref document: AU

Date of ref document: 20111207

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013/06919

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011847739

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13130

Country of ref document: GE

Ref document number: 13147794

Country of ref document: CO

Ref document number: 2011847739

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201390844

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201307936

Country of ref document: UA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013013415

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013013415

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130529